https://doi.org/10.55788/3d86e7fc
“To date, no randomised trials have been conducted comparing USAT and SPE as reperfusion strategies in patients with intermediate-high or high-risk pulmonary embolism,” said Dr Stefan Stortecky (University of Bern, Switzerland) [1]. The single-centre, randomised-controlled, non-inferiority, phase 2 SPECIAL trial investigated this matter. The primary endpoint was the difference in right to left ventricular dimension ratio (RV/LV ratio), assessed by contrast-enhanced chest CT from baseline to 72 hours. “The trial was ended prematurely due to the difficulty of enrolling patients in the emerging era of less-invasive endovascular techniques,” added Dr Stortecky. Thus, the trial included 27 instead of the planned 60 participants.
Both treatment options resulted in significant mean changes in RV/LV ratio from baseline to 72 hours: for USAT 1.43 to 1.09 (P<0.001) and for SPE 1.47 to 0.94 (P<0.001). However, USAT was not non-inferior to SPE (mean change 0.34 vs 0.53; Pnon-inferiority=0.80). In addition, the P-value for superiority was 0.013 in favour of the SPE arm. Other endpoints, such as the Qanadli Obstruction Index and the total number of fully and partially occluded segments also indicated that SPE led to better treatment results than USAT.
Finally, there were no significant differences in safety outcomes, including the rate of recurrent VTE (SPE vs USAT, 14% vs 0%) and any bleeding (SPE vs USAT, 14% vs 23%). No deaths or strokes were reported in the current trial.
Dr Sahil Parikh (Columbia University Irving Medical Center, NY, USA) commented that there are several catheter-based treatment options effective in reducing the RV/LV ratio in 2023 and that the remaining role of SPE in this era still needs to be determined. “We see a movement towards mechanical thrombectomy and because this approach delivers more rapid clinical improvement, it offers the opportunity to avoid thrombolytics and may result in less need for an ICU stay,” he decided.
- Stortecky S, et al. Ultrasound-assisted catheter-directed thrombolysis versus surgical pulmonary embolectomy for intermediate-high or high-risk pulmonary embolism: a randomised phase 2 non-inferiority study. FS07, AHA Scientific Sessions 2023, 11–13 November, Philadelphia, PA, USA.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Abelacimab substantially lowers bleeding risk compared with rivaroxaban Next Article
Can a walking intervention improve functional status and quality of life in HFrEF? »
« Abelacimab substantially lowers bleeding risk compared with rivaroxaban Next Article
Can a walking intervention improve functional status and quality of life in HFrEF? »
Table of Contents: AHA 2023
Featured articles
Abelacimab substantially lowers bleeding risk compared with rivaroxaban
Hot Topics in CAD/PAD
MINT: Liberal or restrictive transfusion strategy in MI with anaemia?
ORBITA-2 confirms PCI effective for symptom relief in patients with stable angina
Nicotinamide riboside shows promising trend for walking function in PAD
Pemafibrate reduces microvascular complications of PAD and T2D
Dapagliflozin improves cardiometabolic outcomes in myocardial infarction
Optimising Hypertension Outcomes
Edoxaban versus warfarin in chronic thromboembolic pulmonary hypertension
Sodium intake and blood pressure: new insights
Post-partum intervention lowers BP after hypertensive pregnancy
Biannual zilebesiran associated with substantial BP reductions
Future of Lipid-Lowering Therapies
Encouraging data for lepodisiran as Lp(a) lowering therapy
Gene editing may change the treatment landscape of hypercholesterolaemia
REPRIEVE: Mechanisms behind MACE reduction in HIV population on pitavastatin
Recaticimab may offer a solution for uncontrolled hypercholesterolaemia
Atrial Fibrillation and Sudden Cardiac Death
Abelacimab substantially lowers bleeding risk compared with rivaroxaban
Liraglutide may improve post-ablation outcomes in obese patients with AF
Single or dual cardioversion in patients with obesity and AF?
NOAH-AFNET 6: Does the duration of AHRE influence response to edoxaban?
ARTESIA: How useful is anticoagulation in subclinical AF?
Jewel IDE: High compliance rates for novel patch wearable cardioverter defibrillator
Sudden cardiac death in athletes: incidence, causes, and trends over 20 years
Miscellaneous Trials
Successful results for semaglutide in the highly anticipated SELECT trial
Can a walking intervention improve functional status and quality of life in HFrEF?
Head-to-head: Surgical embolectomy versus ultrasound-assisted thrombolysis in high-risk pulmonary embolism
Related Articles
October 30, 2023
Should we use anticoagulation in AHRE to prevent stroke?
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com